IMR Press / FBL / Volume 27 / Issue 1 / DOI: 10.31083/j.fbl2701010
Open Access Original Research
Combinatorial approach of vitamin C derivative and anti-HIV drug-darunavir against SARS-CoV-2
Show Less
1 Department of Skin and VD, Institute of Medical Sciences & SUM Hospital, Siksha ‘O’ Anusandhan Deemed to be University, 751002 Bhubaneswar, Odisha, India
2 Division of Microbiology and NCDs, ICMR-Regional Medical Research Centre, 751023 Bhubaneswar, Odisha, India
3 Department of Zoology, Redox Regulation Laboratory, Odisha University of Agriculture and Technology, College of Basic Science and Humanities, 751003 Bhubaneswar, India

Academic Editor: Biswaranjan Paital

Front. Biosci. (Landmark Ed) 2022 , 27(1), 1;
Submitted: 20 April 2020 | Revised: 13 April 2021 | Accepted: 27 May 2021 | Published: 11 January 2022
(This article belongs to the Special Issue Aging in animals)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: Coronavirus disease-2019 (COVID-19) has become a pandemic around the globe due to the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), a new variant of the Coronavirus (CoV) family. The rapid transmission of the infectious disease, 135,646,617 positive cases from which 2,930,732 mortality cases were recorded until 11 April 2021. In an emergency, several existing anti-viral, anti-malarial, and anti-HIV drugs have been used on a repurposing basis. However, without proper clinical evidence, it may create several side effects for the patient. Thus, recommending potential and less-toxic regimens at this emergency stage is the most crucial aspect for any physician. Methods: We have hypothesized a combinatorial drug approach against COVID-19 and to select potential combinations from ten anti-HIV drugs and ten vitamin C derivatives were systematically validated using advanced bioinformatic tools. Initially, the chemical structures used as ligands from PubChem and the target protein, SARS-CoV-2 main protease (PDB ID: 6Y84) from the protein data bank were retrieved for this study. Further, assess the potency, toxicity, drug-ability, and pharmacokinetics profiles using several bioinformatics tools, viz., molecular docking by the AutoDock 4.1 software with predicting activity spectra for substances, Molsoft, ProTox, and SwissADME tools. Molecular dynamics simulation was also employed for most potential candidates to assess their binding stability using GROMACS 5.1.4 software. Results: The above computational investigation indicated that ‘darunavir with L-ascorbyl-2,6-dibutyrate or ascorbic acid-2-sulfate’ combinations strongly inhibit the SARS-CoV-2-main protease as a potential treatment option against COVID-19. Mostly, vitamin C derivatives enhanced the anti-COVID activity and might reduce the post-treatment side effects of darunavir in combination. Conclusions: Overall, the present work suggests that bioinformatics tools are suitable for recognizing potential candidates in an emergency, and herein the selected ‘anti-HIV-drug-vitamin c derivatives’ cocktails may potential-cum-fewer toxic regimens against COVID-19 treatment.

Primary health care
Compute-aided drug design
Combinatorial drug approach
1. Introduction

The emerging Coronavirus disease-2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has continuously added a higher number of morbidity and mortality cases, globally [1, 2, 3]. Under this unrestrained grievous health endemic situation, the World Health Organization (WHO) has declared it as a Public Health Emergency of International Concern [1, 4]. The outbreak and quick transmission of the COVID-19 is terrible than the previously emerged SARS-CoV and any other viral diseases [2, 5]. The symptoms exhibited by the patients under COVID-19 infection are similar to that of the previously SARS-CoVs infection, including fever-cough, complicity during the breath, muscle pain, sore throat and sputum production. However, severe pneumonia and multi-organ dysfunction under COVID-19 infection have been found to enhance the mortality rate, predominantly in immune-compromised patients, i.e., in the elderly age group (>60 years) and patients with co-morbidities [4, 6].

The food and drug administration (FDA) has not recommended any drug(s) rather re-purposed a few medications to treat this harmful infectious disease to tackle the pandemic in an emergency. However, fighting against the emerging aggressive positive-sense single-strand RNA or (+) ssRNA viral infection without effective medicine is the most significant panic situation for protecting the global health system [7, 8]. Indeed, experts or physicians used several alternative combinations of existing anti-viral, anti-malarial, anti-HIV (human immunodeficiency virus), and anti-inflammatory drugs on a non-random trial basis without much clinical experience to control the situation [6, 9, 10]. Mainly, approved anti-viral drugs such as baloxavir marboxil, darunavir, favipiravir, lopinavir, oseltamivir, remdesivir, ritonavir, etc., along with several immune-modulatory, anti-inflammatory remedies such as Fingolimod, Sarilumab and Tocilizumab are used in multiple combinations against COVID-19 [9, 10, 11]. Even the combined treatment with obsolete anti-malarial quinine derivatives such as hydroxyl-chloroquine with the macrolide (azithromycin) and tetracycline (doxycycline) class of antibiotics is continuously used as an alternative against COVID-19 [11, 12]. The COVID-19 is an aggregated form of previously recognized SARS and the Middle East respiratory syndrome (MERS) virus and its genome was found to have >70% genomic similarity with the previous variants. Thus, previously recommended drug combinations for SARS and MARS on a repurposing basis, now used against SARS-CoV-2. Strategically applied drug combinations or combinatorial formulae seem to yield a positive response against SARS-CoV-2. Nevertheless, several issues also exist with drug dose combination and its post-treatment side effects [13, 14].

In parallel, some claims for using certain Traditional Chinese Medicines (TMC) to control COVID-19 [15, 16]. In collaboration with the State Administration of Traditional Chinese Medicine, the Hubei Hospital of Traditional Chinese Medicine filed a trial application to start the phase-I clinical trial with a health-boosting TMC formulation against COVID-19 [17]. Similarly, few also claim for the use of Ayurvedic and Homeopathic formulations from the Indian Unani system and other Western traditional medicines for the treatment of COVID-19 [18, 19]. As per previous reports, homeopathic remedies also successfully prevented Cholera, Spanish Influenza, Yellow fever, and Typhoid diseases [20, 21, 22]. Thus, locating an active and non-toxic/less toxic combinatorial approach is essential in this emergency.

Therefore, the present work also proposed an alternative health-boosting and immune-modulating ‘mainstream-natural combined formula’ against COVID-19. High throughput screening approaches were employed in selecting a specific active anti-HIV drug and a vitamin C derivative (VCD) for their possible practice in combination/synergistic for the treatment of COVID-19.

2. Material and methods
2.1 Preparation of ligand and target protein structures for molecular docking study

Based on previous literatures and research findings, ten anti-HIV protease inhibitor drugs namely, amprenavir (PubChem ID: 65016), ASC09 (PubChem ID: 53361968), atazanavir (PubChem ID: 148192), darunavir (PubChem ID: 213039), indinavir (PubChem ID: 5362440), lopinavir (PubChem ID: 92727), nelfinavir (PubChem ID: 64143), ritonavir (PubChem ID: 392622), saquinavir (PubChem ID: 441243), tipranavir (PubChem ID: 54682461) and vitamin Cor L-ascorbic acid (PubChem ID: 54670067) as a code, VCD-1 with another nine VCDs, VCD-2 (2-O-α-D-glucopyranosyl-l-ascorbic acid with a PubChem ID: 54713602), VCD-3 (L-ascorbyl 2,6-dibutyrate with a PubChem ID: 54693078), VCD-4 (glyceryl ascorbate with a PubChem ID: 67266814), VCD-5 (3-O-ethyl-l-ascorbic acid with a PubChem ID: 150736, VCD-6 (ascorbic acid 2-sulfate with a PubChem ID: 54675759), VCD-7 (6-deoxy-l-ascorbic acid with a PubChem ID: 54679898), VCD-8 (5,6-diacetoxy-l-ascorbic acid with a PubChem ID: 54682503), VCD-9 (3-O-methyl-l-ascorbic acid with a PubChem ID: 11805516), VCD-10 (3,4-dihydroxy-5-(1-hydroxy-2-acetoxyethyl)furan-2(5H)-one with a PubChem ID: 54718197) were retrieved from PubChem data base ( as ligands for docking against the retrieved three-dimensional protein structure of SARS-CoV-2-protease. Later on, the target enzyme (main protease of SARS-CoV-2 with PDB ID: 6Y84) was retrieved from the protein data bank. The software Avogadro 1.2 was used for the energy minimization of each ligand before the docking study.

Initially, each ligand chemical structure was converted to dot PDB (.pdb) data format, as a required format according to the used docking software, AutoDock 4.1. Later on, based on the binding pattern or molecular interactions from high-throughput molecular docking study against SARS-CoV-2 protease, the lead anti-HIV drugs and VCDs were selected [23, 24]. The molecular docking was performed, followed by a multi-step AutoDock tutorial. Again, a double docking study was conducted to assess the combinatorial action of both leading anti-HIV drugs and ascorbic acid derivatives against the same target SARS-CoV-2 protease [25, 26, 27]. The molecular interaction and binding pattern of protein-ligand docking complexes were visualized by BIOVIA DSV v 4.5 software [28].

2.2 Possible biological activity prediction and drug-likeness analysis

Furthermore, the physicochemical properties such as molecular weight (MW), number of hydrogen acceptors (H-BA) and donors (H-BD), topological surface area (tPSA), partition or distribution coefficient (XLogP) value, number of rotatable-bonds (RB), molar refractivity (MR), collectively known as standardized Lipinski rules of five (RO5) parameters were recorded from PubChem database. The overall drug-likeness score of individual anti-HIV drugs and VCDs properties was recorded using the tool, MolSoft (

Again, to predict the possible therapeutic potencies such as vaso-protective, respiratory analeptic, immuno-stimulant, antioxidant, anti-inflammatory and anti-viral properties of ascorbic acid and their derivatives through the advanced bioinformatics tool, the Perdition of Activity Spectra for Substances (PASS) ( was used. The specific biological activities of each candidate as per the present objectives, probable activity (Pa) and probable inactivity (Pi) values were recorded through data mining processes against the training data set presented in the PASS data library.

2.3 Toxicity and pharmacokinetics profile analysis

The tool, ProTox (, was employed to predict the probable toxicity profiles such as hepatotoxicity, carcinogenicity, immunotoxicity toxicity, mutagenicity, cytotoxicity, toxicity class and lethal dose (LD50) values of the selected anti-HIV drugs as well as VCDs. Simultaneously, the Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties were assessed using the tool, SwissADME ( for each candidate.

2.4 Molecular-dynamics simulation of selected protein-ligand complexes

To check the stability/flexibility of docking complexes, selected two docking complexes (based on the effective docking score), from each side (one from anti-HIV drugs, i.e., ‘main protease-darunavir’ and one from VCDs, namely, ‘main-protease- ascorbic acid-2-sulfate or VCD-6’ were selected for MD simulation with the software GROMACS 5.1.4 (Groningen Machine for Chemical Simulations) in the GROMOS force field in 50 ns time scale [25, 26, 27]. In the first step, we have generated topologies files for each complex using the PRODRG server ( Selected docking complexes with the SPC-E water-cubic box model (whose volume was about 976.40, 976.50, 977.48, 977.48 nm3, respectively) were simulated and then added a total of 30576, 30564, 30573 and 30563 numbers of solvent molecules to each system of docking complexes. Concurrently, neutralized the system by adding 4 Na+ ions and the energy minimization using 50,000 steepest descent steps for each docking complex. After minimizing the system, the NVT (number of particles, volume and temperature) and NPT (number of particles, pressure, temperature) equilibrations were performed for equilibrating the system for the 100 ps time scale and a 50 ns time scale of MD simulation was performed [25, 26, 27].

3. Results
3.1 Preparation of ligand and target protein structures for molecular docking study

As per the research hypothesis, the docking scores (kcal/mol) were used as a standard parameter for selecting the most efficient combination of any vitamin C derivatives with a potent anti-HIV drug against deadly SARS-CoV-2 (Tables 1,2). The docking score of L-ascorbic acid and derivatives was within -7.00 kcal/mol. Among all derivatives, the VCD-6 (ascorbic acid 2-sulfate) with docking score -6.75 (Fig. 1), and the VCD-3 (L-ascorbyl 2,6-dibutyrate) with docking score -6.19 kcal/mol (Fig. 2) were chosen for further studies (Table 1). On the other hand, all the selected ten anti-HIV drugs had docking scores within -11.00 kcal/mol (Table 2). Darunavir was chosen from all anti-viral drugs as the most active drug against SARS-CoV-2 protease, based on the docking a score, -10.25 kcal/mol (Fig. 3). Therefore, based on the overall docking score and molecular interactions, the VCD-6 and VCD-3 among vitamin C derivatives, and darunavir among all ten anti-viral drugs were selected for further studies.

Table 1.Recorded docking scores and ligand efficacy against protease of SARS-CoV-2 virus (PDB ID: 6Y84) and overall drug-likeness scores, lethal doses and bioavailability scores of VCDs based on chemical structures.
VCDs Docking score in kcal/mol (type of interaction and their bond length) Drug likeness score Lethal dose (mg/kg) Bioavailability score
VCD-1 −4.94 (Lys5: Conventional-H-bond 2.50 Å; Trp207: Conventional-H-bond 2.04 Å; Leu282: Conventional-H-bonds 1.97 Å & 2.19 Å; Ser284: Conventional-H-bond 2.03 Å; Glu288: Conventional-H-bonds 1.81 Å & 2.23 Å) 0.74 3367 0.56
VCD-2 −2.87 (Pro52: Conventional-H-bonds 1.86 & 1.90 Å; Asn53: Conventional-H-bond 1.97 Å; Tyr54: Conventional-H-bond 2.0 Å; Glu55: Conventional-H-bonds 1.92, 2.68 Å) 0.53 25000 0.11
VCD-3 −6.19 (Lys5: Conventional-H-bonds 2.03 Å, 2.31 Å & 2.50 Å; Gly127: Conventional-H-bonds 2.27 Å & 2.91 Å) 0.34 25000 0.56
VCD-4 −4.56 (Arg4: Conventional-H-bond 2.13 Å-Carbon-H-bond 3.03 Å; Lys5: Conventional-H-bond 2.32 Å; Trp207: Conventional-H-bond 2.07 Å; Leu282: Conventional-H-bond 2.20 Å; Ser284: Conventional-H-bonds 1.90, 2.09 & 2.30 Å) 0.80 5000 0.56
VCD-5 −4.78 (Phe3: Carbon-H-bond 3.46 Å; Lys5: Conventional-H-bond 2.0 Å; Trp207: Conventional-H-bond 2.39 Å; Leu282: Conventional-H-bonds 1.72 Å & 1.89 Å; Ser284: Conventional-H-bond 2.11 Å; Glu288: Conventional-H-bond 2.07 Å) 0.27 5000 0.56
VCD-6 −6.75 (Phe3: Conventional-H-bond 2.18 Å; Arg4: Conventional-H-bond 2.10 Å; Lys5: Conventional-H-bonds-1.68, 1.70, 2.18, 2.83, 3.10 Å; Glu288: Conventional-H-bond 2.24 Å) 0.24 10000 0.11
VCD-7 −5.61 (Phe3: Conventional-H-bond-2.17 Å; Arg4: Conventional-H-bond-2.95 Å- Carbon-H-bond 3.70 Å; Trp207: Conventional-H-bond 2.15 Å; Leu282: Conventional-H-bonds 1.81 Å & 2.25 Å; Ser284: Conventional-H-bond 2.34 Å) 0.11 5000 0.56
VCD-8 −5.98 (Lys5: conventional-H-bond 2.05, 2.16, 2.56 & 2.61 Å; Gln127: Conventional-H-bonds 2.19, 2.23 & 2.45 Å) 0.12 5000 0.56
VCD-9 −4.72 (Phe3: Carbon-H-bond 3.71 Å; Lys5: Conventional-H-bonds 2.55, 2.53, 2.58 & 2.71 Å; Leu282: Conventional-H-bonds 1.78 & 2.18 Å; Ser284: Conventional-H-bond 1.78 Å-Carbon-H-bond 3.63 Å) 0.45 5000 0.56
VCD-10 −5.79 (Lys5: Conventional-H-bonds 1.90, 1.93, 2.42 & 2.57 Å; Van125: Conventional-H-bond 2.09 Å; Gln127: Conventional-H-bonds 2.03 & 2.36 Å) 0.41 5000 0.56
VCD-1, L-ascorbic acid; VCD-2, 2-O-α-D-glucopyranosyl-l-ascorbic acid; VCD-3, L-ascorbyl 2,6-dibutyrate; VCD-4, glycerylascorbate; VCD-5, 3-O-ethyl-l-ascorbic acid; VCD-6, ascorbic acid 2-sulfate; VCD-7, 6-deoxy-l-ascorbic acid; VCD-8, 5,6-diacetoxy-l-ascorbic acid; VCD-9, 3-O-methyl-l-ascorbic acid; VCD-10, ascorbic acid-6-acetate.
Table 2.Recorded docking scores and ligand efficacy against protease of SARS-CoV-2 virus (PDB ID: 6Y84) and overall drug-likeness scores, lethal doses and bioavailability scores of individual anti-HIV drugs based on chemical structures.
Anti-HIV drugs Docking score in kcal/mol (type of interaction and their bond length) Drug likeness score Lethal dose (kg/mg) Bioavailability score
Amprenavir −8.43 (Lys5: Pi-alkyl 5.1 Å-Pi-cation 4.1 Å; Ala7: Pi-alkyl-3.98 Å; Gln127: Conventional-H-bond 1.66 Å-Carbon-H-bond 3.35 Å; Glu290: Pi-anion 3.50 Å) 1.14 300 0.55
ASC09 −9.56 (Lys5: Conventional-H-bonds 1.96 & 2.01 Å-Pi-alkyls 4.76 & 4.82 Å; Ala7: Conventional-H-bond 1.86 Å-Pi-alkyls 4.45 Å & 4.76 Å; Ala116: Pi-alkyl 5.17 Å; Gly124: Pi-sigma-3.84 Å; Val125: Conventional-H-bond 1.72 Å-Carbon-H-bond 2.87 Å; Tyr126: Pi-alkyl 5.01 Å-Pi-sigma 3.52 Å) 1.09 150 0.17
Atazanavir −7.37 (Arg4: Conventional-H-bond-2.42 Å; Lys5: Conventional-H-bond 2.28 Å; Ala7: Pi-alkyl 5.30 Å; Gln127: Carbon-H-bonds 3.28 & 3.44 Å; Lys137: Pi-alkyl 5.30 Å-Pi-cation 4.70 Å; Asp289: Pi-anion 3.69 Å) 0.11 200 0.17
Darunavir −10.25 (Arg4: Pi-alkyl 4.85 Å-Pi-loan pair 2.75 Å; Lys5: Conventional-H-bonds 2.70 & 2.63 Å-Pi-loan pair 3.34 Å-Pi-alkyl 4.43 Å; Tyr126: Pi-alkyls 4.34 & 4.43 Å; Leu282: Conventional-H-bond 2.85 Å; Glu288: Pi-anions 4.17 & 4.20 Å) 0.60 245 0.55
Indinavir −7.80 (Arg4: Conventional-H-bond 2.14 Å-Carbon-H-bond 3.23 Å; Lys137: Pi-alkyls 3.97 & 5.10 Å; Leu286: Pi-alkyl 5.42 Å; Glu288: Pi-anions 3.44 & 3.99 Å) 1.86 5000 0.55
Lopinavir −9.00 (Arg4: Pi-alkyls 5.31 & 5.48 Å; Lys5: Conventional-H-bond-2.20 & 2.66 Å; sulfurs 2.88 & 2.94 Å; Ser284: Conventional-H-bond 2.14 Å; Glu288: Conventional-H-bond-2.07 Å) 1.10 5000 0.55
Nelfinavir −9.97 (Asn133: Conventional H-bond 1.73 Å; Gly195: Conventional H-bond 1.94 Å; Thr198: Pi-sigma 3.67 Å) 1.41 600 0.55
Ritonavir −8.75 (Arg4: Conventional-H-bonds 1.71 & 2.0 Å-Carbon-H-bond 3.76; Lys5: Conventional-H-bonds 2.51 & 2.56 Å; Lys137: Pi-alkyl 4.43 Å; Val171: Pi-alkyl 5.38 Å; Leu286: Pi-alkyl 4.93 Å; Glu288: Pi-alkyl 4.93 Å-Pi-anion 3.41 Å) 0.11 1000 0.17
Saquinavir −8.97 (Lys5: Pi-alkyl 4.48 Å; Ala7: Pi-alkyl 4.10 Å; Gln127: conventional-H-bond 2.44 & 3.04 Å; Lys137: Conventional-H-bond 2.23 Å; Leu286: Pi-alkyl 4.64 & 5.11 Å) 0.69 500 0.17
Tipranavir −9.98 (Lys5: Pi-alkyl 4.62 Å-Pi-cation 4.64 Å; Ala7: Pi-alkyl 4.46 Å; Tyr126: Pi-alkyl 3.93 Å; Gln127: Conventional-H-bond 1.77 Å; Cys128: Pi-alkyl 4.76 Å; Glu288: Pi-anion 3.13 & 3.44 Å) 0.72 333 0.56
Fig. 1.

Molecular interaction of most effective VCD, VCD-6 (ascorbic acid 2-sulfate) with docking score -6.75 kcal/mol against SARS-CoV-2 protease from docking study.

Fig. 2.

Molecular interaction of most effective vitamin C derivative, VCD-3 (L-ascorbyl 2,6-dibutyrate) with docking score -6.19 kcal/mol against SARS-CoV-2 protease from docking study.

Fig. 3.

Molecular interaction of second most effective most anti-HIV drug, darunavir with docking score, -10.25 kcal/mol against SARS-CoV-2 protease from docking study.

Likewise, a double docking study between darunavir and VCD-6 and VCD-3 against SARS-CoV-2 main protease (VCD-6 and VCD-3 were re-docked against main protease-darunavir docking complex, individually) was performed. It was discernable that the docking score between darunavir and VCD-6 (ligand-ligand) was only -2.05 kcal/mol, but the score was elevated to -10.76 kcal/mol when dual ligands (protein – ligand + ligand) were used in docking studies. Similarly, the docking score between darunavir and VCD-3 alone was -2.45 kcal/mol and the score was found to be enhanced to -10.39 kcal/mol when dual/second ligands were used in docking studies. As per the present hypothesis, a total docking score of both ligand-ligand and dual docking score of -12.81 and -12.84 kcal/mol were anticipated (Fig. 4). Thus, both VCD-6 and VCD-3 are proposed to be used with darunavir in the combinatorial approach against SARS-CoV-2. According to the structural activity relationship (SAR), VCD-6 was comparatively more active as more hydroxy (-OH) groups support establishing strong-H-bond interaction and sulfate groups support enhancing the biological activity.

Fig. 4.

Combinatorial approach of anti-HIV drug with VCD. (A) Darunavir (in red color) with the VCD-6 (in green color). (B) Darunavir (in red color) with the VCD-3 (in green color) at a time against SARS-CoV-2 protease.

3.2 Possible biological activity prediction and drug-likeness analysis

Several strategies have been used to screen/filter the potential lead drug candidates passing through a specific standard parameter at the early stage of drug discovery. Herein, after docking interaction, we took several ideal drug candidate selection parameters into account for more evidence of drug-ability at the primary stage based on their chemical composition. During the selection of most combinatorial candidates from vitamin C derivatives, all possible biological activities such as anti-oxidant, anti-inflammatory, immune-stimulant, vaso-protective, anti-viral and respiratory analeptic properties were carefully considered and analyzed by the PASS tool (Table 3). From recorded anti-viral values, only VCD-6 and VCD-2 PASS scores, 0.715 > 0.005 and 0.715 > 0.002, respectively, were found to be the most potent and the rest of the derivatives showed moderate anti-viral activity. As per the PASS program, a score 0.700 is considered as a standard score for any biological activity, and scores within 0.700 to 0.500 are considered as average scores, while a score <0.500 is considered as a below average score for any biological activity. Similarly, except for VCD-4, VCD-5, VCD-7 and VCD-10, the rest derivatives were bearing potent antiinflammatory activity (Table 3). However, the most effective derivative based on the docking score, i.e., VCD-6 had moderate immune-stimulant, respiratory analeptic activity. On the other hand, the second-most derivative, i.e., VCD-3 was active in all biological systems with moderate anti-viral (0.599 > 0.006) activity. Overall, both VCDs are proposed to be ideal for use in a combinatorial approach with the selected anti-HIV drug against SARS-CoV-2.

Table 3.Recorded possible biological activity according to objectives of the study of VCDs from the tool, prediction of activity spectra for substances (PASS).
VCDs Vaso-protective Respiratory analeptic Immuno-stimulant Anti-oxidant Anti-inflammatory Anti-viral
VCD-1 0.948 > 0.002 0.339 > 0.092 0.557 > 0.029 0.928 > 0.003 0.779 > 0.008 0.567 > 0.009
VCD-2 0.979 > 0.001 0.980 > 0.003 0.873 > 0.005 0.929 > 0.003 0.742 > 0.011 0.715 > 0.005
VCD-3 0.934 > 0.002 0.916 > 0.004 0.719 > 0.013 0.797 > 0.003 0.804 > 0.006 0.599 > 0.006
VCD-4 0.949 > 0.002 0.879 > 0.005 0.628 > 0.020 0.875 > 0.003 0.595 > 0.033 0.691 > 0.003
VCD-5 0.944 > 0.002 0.951 > 0.003 0.560 > 0.028 0.897 > 0.003 0.603 > 0.031 0.504 > 0.022
VCD-6 0.917 > 0.002 0.523 > 0.033 0.583 > 0.025 0.821 > 0.003 0.703 > 0.015 0.715 > 0.002
VCD-7 0.880 > 0.003 0.890 > 0.004 0.602 > 0.023 0.918 > 0.003 0.603 > 0.031 0.552 > 0.012
VCD-8 0.878 > 0.003 0.876 > 0.005 0.713 > 0.014 0.868 > 0.003 0.931 > 0.004 0.573 > 0.009
VCD-9 0.919 > 0.002 0.914 > 0.004 0.546 > 0.030 0.911 > 0.003 0.615 > 0.028 0.547 > 0.013
VCD-10 0.905 > 0.003 0.964 > 0.003 0.710 > 0.014 0.915 > 0.003 0.860 > 0.005 0.575 > 0.009

Furthermore, based on physicochemical and biological properties, the overall drug-likens score or drug-ability scores of VCDs were recorded (Fig. 5; Table 1). All VCDs were found to possess a favorable positive rating of a drug-ability score to be used as a druggable agent. Notably, VCD-1 and VCD-4 showed comparatively higher drug-ability scores, 0.74 and 0.80, respectively, were recorded. The drug-ability score of VCD-6 and VCD-3 was 0.24 and 0.34, respectively. On the other hand, the drug-likeness score of the most effective anti-HIV drugs, darunavir and tipranavir were recorded to be 0.60 and 0.72, respectively, as per the tool MolSoft (Table 2). The drug-likeness score depends on the chemical composition and characteristics within an acceptable range, such as molecular weight, XlogP value, the number of rotatable bonds, molar refractivity, and the number of hydrogen bond-acceptors and hydrogen bond-donors, topological surface area, etc. As per the principle of MolSoft, the drug-likeness scores range within a 0 to 2 considered in the acceptable drug-likeness score, and less than < 0 and > 2 is considered as a non-drug drug-likeness score for a drug candidate.

Fig. 5.

Overall drug likeness score of two effective most VCDs. (A) VCD-6 (0.24). (B) VCD-3 (0.34), respectively.

3.3 Toxicity and pharmacokinetics profile analysis

The pharmacokinetics and toxicity profile also play a crucial role in the late stage of drug development modules or clinical validation stage before the human recommendation. Thus, the computational tools can predict the possible pharmacokinetic and toxicity profiles of any proposed drug molecule. Accordingly, the used ligands toxicity and the pharmacokinetic profiles were recorded (Tables 4,5). Results indicate that the VCD-anti-HIV drug combination formulation will make it safer and balance the toxicity during administration as VCDs showed potential antioxidative and anti-inflammatory activity. The higher toxicity class-VI for VCD-6 and VCD-3 also indicated that both are non-toxic and safer among all VCDs (Table 4). Additionally, the predicted LD50 values (mg/kg) can be considered another conclusive factor in the approval of VCDs in higher concentrations than the selective anti-HIV drug in the combinatorial approach. The documented pharmacokinetics profiles found that the proposed VCDs in the present study are suitable to be used in combination with mainstream medicine (Table 6; Fig. 6). Further, the blood-brain barrier, gastrointestinal absorption, skin permeation profiles are also satisfied also satisfied as promising drug candidates.

Table 4.Recorded toxicity profiles with color indication along with toxicity class of VCDs from the tool, ProTox.
VCDs Hepatotoxicity Carcinogenicity Immuno-toxicity Mutagenicity Cyto-toxicity Toxicity class
VCD-1 Safest Safest Safest Safest Moderately safe V
VCD-2 Safest Safest Safest Safest Moderately safe VI
VCD-3 Safest Safest Safest Safest Moderately safe VI
VCD-4 Safest Safest Safest Safest Moderately safe V
VCD-5 Safest Safest Safest Moderately safe Moderately safe V
VCD-6 Safest Safest Safest Moderately safe Safest VI
VCD-7 Safest Moderately safe Safest Safest Moderately safe V
VCD-8 Safest Safest Safest Moderately safe Moderately safe V
VCD-9 Safest Safest Safest Safest Moderately safe V
VCD-10 Safest Safest Safest Moderately safe Moderately safe V
The drugs are classified based on the levels of toxicity as Safest and moderately safe.
Table 5.Recorded toxicity profiles with color indication along with toxicity class of anti-HIV drug from the tool, ProTox.
Anti-HIV drugs Hepatotoxicity Carcinogenicity Immunotoxicity Mutagenicity Cytotoxicity Toxicity class
Amprenavir Safest Moderately safe Safest Safest Moderately safe III
ASC09 Moderately safe Moderately safe Toxic/Hazardous Safest Moderately safe III
Atazanavir Moderately safe Moderately safe Safest Moderately safe Moderately safe III
Darunavir Toxic/Hazardous Moderately safe Moderately safe Moderately safe Moderately safe III
Lopinavir Safest Safest Safest Safest Safest V
Indinavir Toxic/Hazardous Moderately safe Toxic/Hazardous Safest Moderately safe V
Nelfinavir Moderately safe Moderately safe Toxic/Hazardous Safest Moderately safe IV
Ritonavir Toxic/Hazardous Moderately safe Safest Safest Moderately safe IV
Saquinavir Moderately safe Moderately safe Safest Safest Safest IV
Tipranavir Toxic/Hazardous Moderately safe Moderately safe Safest Moderately safe IV
The drugs are classified based on the levels of toxicity as Safest, moderately safe and toxic/hazardous.
Table 6.Recorded possible pharmacokinetics profiles of VCDs based on its individual chemical structure against a training set drug molecule using the tool, SwissADME.
VCDs GI-abs. BBB permit P-gp substrate CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor Log Kp (cm/s)
VCD-1 High No No No No No No No −8.54
VCD-2 Low No Yes No No No No No −10.55
VCD-3 High No Yes No No No No No −7.48
VCD-4 Low No No No No No No No −9.69
VCD-5 High No No No No No No No −8.61
VCD-6 Low No No No No No No No −9.45
VCD-7 High No No No No No No No −7.70
VCD-8 High No No No No No No No −8.63
VCD-9 High No No No No No No No −8.78
VCD-10 High No No No No No No No −8.39
BBB, blood-brain barrier; GI-abs., gastrointestinal absorption Log Kp (skin permeation).
Fig. 6.

Overall predicted pharmacokinetics reports of two effective most VCDs. (A) VCD-6. (B) VCD-3.

3.4 Molecular dynamic simulation of selected protein-ligand complexes

The structural stability of selected two docking complexes was analyzed through the root mean square deviation (RMSD)-protein backbone, root mean square fluctuation (RMSF)-C-alpha and Radius of gyration (Rg) of protein by MD simulation in 50 ns time scale (Figs. 7,8). The elucidated RMSD plot for both ‘protease-darunavir’ and ‘protease-VSD-6’ complexes showed a continuous deviation in the backbone protein during 50 ns. Mainly, darunavir holds some stability in stating within 20 ns, while both are in the same fluctuation place at the end, after 45–50 ns (Fig. 7A). At the same from each ligand flexibility study, VCD-6 maintained more stability than darunavir throughout 50 ns (Fig. 7B). Overall, VCD-6 showed comparatively more stability than darunavir from RMSD analysis. Rg-plots and RMSF-plots also showed that both complexes were similar fluctuation with 50 ns MD simulation. Additionally, both ligands could therapeutically potential towards block the viral function through solid H-bond interactions with SARS-CoV-main protease (PDB ID: 6Y84) from the MD simulation (Fig. 8).

Fig. 7.

Conformational stability in the form of RMSD-score. (A) Stability of protease-darunavir’ and protease-VCD-6’ docking complexes. (B) Individual ligand stability in the docked complexes within 0–50 ns in the overlayed figure.

Fig. 8.

Interaction stability analyses in the form of H-bond. (A) H-bond interaction of ‘protease-darunavir’ docking complex. (B) H-bond interaction of ‘protease-VCD-6’ docking complex during 50 ns.

4. Discussion

The advanced computation program presently plays an ideal platform to accelerate the drug discovery process with minimal resources and time during the selection of lead drug candidates [26, 28, 29]. Indeed, advanced computational intelligence is able to mimic the entire human living system through coding/programming languages. Molecular docking is one of the efficient computational platforms used for locating active therapeutic agents, based on the interaction between the targeted enzyme and ligand complexes [25, 28]. Molecular docking has also been applied since the last decade to efficiently screen out several potential drug molecules than traditional wet-laboratory approaches. Theoretically, docking score is the sum of the individual molecular interaction of the ligand with the target protein, where types of bonds (conventional H-bond is stronger than other bond formation), bond-length (lesser in the distance (Å) consider as more in strength) [25, 26, 27]. For example, VCD-6 showed an effective docking score as most of the interactions in their complex formed with H-bonds with minimum bond-length (Å) (Table 1). Thus, it will continue to play an essential role in early drug discovery before experimentation [28, 29, 30]. Several pharmaceutical industries and exclusive drug research laboratories/stations are also using this advanced technique in novel drug development cascades [29, 31].

On the other hand, natural products are always vital for nutraceuticals, pharmaceutical supplements, especially against infectious diseases [32, 33]. Identified several unique secondary metabolites from different medicinal and aromatic plants are continuously used in different ways for control of several human health ailments [20, 32, 33]. Indeed, natural products have been in use in several developed western countries as Complementary and Alternative Medicine (CAM) [20, 34, 35]. Approximately 48% of the population in Australia, 70% in Canada, 42% in the USA, 38% in Belgium and 75% in France communities use phytoextract as CAM in day-to-day life [36]. Indeed, WHO also emphasizes developing or locating natural-product(s) based drug candidates for mainstream use. Simultaneously, ascorbic acid or vitamin C derivatives, having a wide range of biological activity against respiratory tract infection, with anti-bacterial, anti-viral and potent immune-stimulant activities [37, 38, 39, 40]. Recently, some non-clinical reports also indicate that vitamin C has potent anti-SARS-CoV-2 activity and is now under clinical validation too (trail no. NCT04323514). On the other hand, anti-HIV drugs are the most suitable therapeutic choice against SARS-CoV-2, as previously exhibited positive response against SARS and MARS on a repurposing basis with severe side effects from long-term practice. Thus, the present attempt with a suitable anti-oxidative and immune-stimulant natural regimen based-combinatorial approach towards control of SARS-CoV-2 may minimize the host toxicity.

In the present scenario, finding a newer drug candidate is a challenge. Most pharmaceutical companies face the same problem as selected lead candidates disappointment in clinical trials due to lack of drug-likeness property, even reported active in preliminary in vitro and in vivo testing [33, 36, 41]. Thus, biological activity is a primary parameter for to establishing a lead candidate and several other standard parameters should be followed during clinical trial investigation for recognition in mainstream medicine. The advanced artificial inelegance platform analyzed this parameter for any desired or unknown chemical through a data mining procedure. Hence, the drug-ability investigation based on high throughput computational screening is more beneficial to keep a suitable drug lead candidate at the early stage [23, 24, 25, 26, 27, 28].

Several mainstream medicines come from natural resources or contain active biological scaffolds/constituents and require continuous exploration of more natural products to utilize in mainstream medicine to fulfill the unavailability of drugs in an emergency [32, 42]. The current bioassay-guided plant extraction and characterization methods have isolated many active secondary metabolites for therapeutic uses. At the same time, advanced medicinal chemistry and bioinformatics tools currently help locate active candidates targeting any specific pathogen/disease to accelerate and give enough reports for early drug discovery [41, 42]. Under the emergency, this selected combination could be the right option than any non-clinical hit-and-trial prescription to treat SARS-CoV-2 infected patients. Notably, using two anti-HIV drugs might be associated with a higher risk of hepatic and liver injury to patients. Thus, potent vitamin C could be the right candidate with an anti-HIV drug to manage side effects for its anti-oxidative, anti-inflammatory potency, immune-stimulant, with anti-viral efficacy.

Today, COVID-19 is the most significant pandemic in the 21st century caused by the aggressive mutant SASR-CoV-2 strains in a different interval that the world has been observing since the end of 2019. The lockdown and social distancing as preventive actions to break/pause the viral cycle within the community. However, potential and exclusively vaccine/therapeutic is essential to control the gruesome SARS-CoV-2 strain [43, 44, 45]. The combinatorial drug therapy as projected herein using existing medicines and the knowledge of traditional Indian medicine/Ayurveda and traditional Chinese medicine is ingenious and motivated attempts towards control of SARS-CoV-2 and reduces adverse effects from repurposing drugs.

5. Conclusions

From the management and treatment points of view, physicians used several alternative combinations of existing anti-viral, anti-inflammatory and anti-malarial drugs with less clinical experience to tackle the situation of SASR-CoV-2 infection on a case-by-case basis. Still, the post-treatment side effects of two mainstream medicines used in combination drug therapy are under debate. Thus, the present study intends to find a possible potent combinatorial approach with an existing anti-HIV drug, darunavir with a vitamin C derivative against SARS-CoV-2. The potent combination was verified in a cost-effective drug development platform and suggested based on advanced PASS prediction, molecular docking, toxicity-pharmacokinetic profile prediction and MD simulation analyses. It could be a dominant synergistic formula of a natural derivative with an anti-HIV drug to control COVID-19 infection and is expected to produce negligible toxicity due to the presence of anti-oxidative, anti-inflammatory and immune-stimulant natural vitamin C derivative with darunavir. In an emergency, the computer-aided drug design approach utilizing present clinical evidence and genomic information on SARS-CoV-2 gives hints to investigate natural products for its treatment. Finally, verifications of the essential features of prospective drugs loom large ordinarily to a traditional pharmacologist, who would blithely accept the results of bioinformatics analyses for promotion towards drug development screening.


ADMET, absorption, distribution, metabolism, excretion and toxicity; CAM, complementary and alternative medicine; COVID-19, coronavirus-2019 disease; FDA, food and the drug administration; H-bond, hydrogen bond; HIV, human immunodeficiency virus; LD50, lethal dose; MERS, middle East respiratory syndrome; MD simulation, molecular dynamics simulation; MR, molar refractivity; MW, molecular weight; NPT, number of particles, pressure, temperature; NVT, number of particles, volume and temperature Pa, probable activity; PASS, perdition of activity spectra for substances; Pi, probable inactivity; RB, rotatable-bonds; Rg, Radius of gyration; RMSD, root mean square deviation; RMSF, root mean square fluctuation; RO5, Lipinski rules of five; SAR, structural activity relationship; SARS-CoV-2, severe acute respiratory syndrome corona virus-2; TMC, traditional Chinese medicines; tPSA, topological surface area; VCD, vitamin C derivative; WHO, World Health Organization.

Author contributions

SSS and AS designed and hypothesized the concept. AS carried out the computational work under the guidance of SSS. SSS and AS drafted the MS. BP and MP carefully reviewed and commented on the final MS. All authors contributed to manuscript revision, read, and approved the submitted version.

Ethics approval and consent to participate

Not applicable.


We are thankful to the Dean, Institute of Medical Sciences & SUM Hospital, Siksha ‘O’ Anusandhan Deemed to be University and the Director, ICMR-Regional Medical Research Centre, Bhubaneswar, for encouragement during the preparation of the MS and special thanks to the World Health Organization for updated information on SARS-CoV-2. The entire work is dedicated to science and all heroes (doctor, nurse, pharmacist, media, police, soldier, and associated leader) who fight against SARS-CoV-2 for us.


This work is sincerely acknowledged to S‘O’A University in-house Ph.D. fellowship support to Miss. Alaka Sahoo (Biotechnology Regd. No.: 1981611009) and ICMR-Post Doctoral Fellowship award to Dr. Shasank S. Swain (No.3/1/3/PDF[21]/HRD-2019-2) by the Indian Council of Medical Research, Govt. of India, New Delhi.

Conflict of interest

The authors declare no conflict of interest.

World Health Organization. Novel coronavirus—China. 2020. Available at:–novel-coronavirus-china/en/ (Accessed: 22 April 2020).
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395: 470–473.
WY Khot, MY Nadkar. The 2019-novel coronavirus outbreak—a global threat. Journal of the Association of Physicians of India. 2020; 68: 67–71.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Military Medical Research. 2020; 7: 11.
Giwa A, Desai A. Novel coronavirus COVID-19: an overview for emergency clinicians. Emergency Medicine Practice. 2020; 22; 1–21.
Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerging Microbes & Infections. 2020; 9: 687–690.
Yoo YH. Convalescent plasma therapy for corona virus disease 2019: a long way to go but worth trying. Journal of Korean Medical Science. 2020; 35: e150.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: A retrospective cohort study. Journal of Infection. 2020; 81: e1–e5.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatment for coronavirus disease 2019 (COVID-19): A review. Journal of the American Medical Association. 2020; 323: 1824–1836.
Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020; 367: 1412–1413.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020; 56: 105949.
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49: 147–157.
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China—key questions for impact assessment. The New England Journal of Medicine. 2020; 382: 692–694.
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacological Research. 2020; 155: 104743.
Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019–new coronavirus (SARS-CoV-2): A review and perspective. International Journal of Biological Sciences. 2020; 16: 1708–1717.
Chinese clinical trial register (ChiCTR)—The world health organization international clinical trials registered organization registered platform. 2020. Available at: (Accessed: 22 April 2020).
AYUSH advisory for corona virus. 2020. Available at: (Accessed: 20 April 2020).
Sarkar P, Lohith Kumar DH, Dhumal C, Panigrahi SS, Choudhary R. Traditional and ayurvedic foods of Indian origin. Journal of Ethnic Foods. 2015; 2: 97–109.
Kumar Verma A, Kumar V, Singh S, Goswami BC, Camps I, Sekar A, et al. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies. Biomed Pharmacother. 2021; 137: 111356.
Fritts M, Crawford C, Quibell D, Gupta A, Jonas W, Coulter I, et al. Traditional Indian medicine and homeopathy for HIV/AIDS: a review of the literature. AIDS Research and Therapy. 2008; 5: 25.
Srinivasan R, Sugumar VR. Spread of Traditional Medicines in India. Journal of Evidence-Based Complementary & Alternative Medicine. 2017; 22: 194–204.
Kontoyianni M. Docking and Virtual Screening in Drug Discovery. Methods in Molecular Biology. 2017; 44: 255–266.
Swain SS, Paidesetty SK, Padhy RN. Synthesis of novel thymol derivatives against MRSA and ESBL producing pathogenic bacteria. Natural Product Research. 2019; 33: 3181–3189.
Swain SS, Paidesetty SK, Padhy RN. Development of antibacterial conjugates using sulfamethoxazole with monocyclic terpenes: A systematic medicinal chemistry based computational approach. Computer Method Program Biomed. 2017; 140: 185–194.
Mishra P, Paital B, Jena S, Swain SS, Kumar S, Yadav MK, et al. Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFĸB/AKT/mTOR/KEAP1 signalling in rat heart. Scientific Reports. 2019; 9: 7408.
Swain SS, Paidesetty SK, Dehury B, Sahoo J, Vedithi SC, Mahapatra N, et al. Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy. Journal of Cellular Biochemistry. 2018; 119: 9838–9852.
Wagal O. Studies in molecular modeling, in-vitro CDK2 inhibition and antimetastatic activity of some synthetic flavones. Frontiers in Bioscience. 2021; 26: 664–681.
Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. British Journal of Pharmacology. 2011; 162: 1239–1249.
Wang C, Greene D, Xiao L, Qi R, Luo R. Recent developments and applications of the MM/PBSA method. Frontiers in Molecular Biosciences. 2018; 4: 87.
Gioia D, Bertazzo M, Recanatini M, Masetti M, Cavalli A. Dynamic docking: A paradigm shift in computational drug discovery. Molecules. 2017; 22: 2029.
Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. Journal of Natural Products. 2016; 79: 629–661.
Shen B. A New Golden Age of Natural Products Drug Discovery. Cell. 2015; 163: 1297–1300.
Lee J, Bielory L. Complementary and Alternative Interventions in Atopic Dermatitis. Immunology and Allergy Clinics of North America. 2010; 30: 411–424.
Bhandari N. Is ayurveda the key to universal healthcare in India? British Medical Journal. 2015; 350: h2879–h2879.
WHO. Marketing authorization of new medicines in the EU: towards evidence-based improvement. 2013. Available at: (Accessed: 13 April 2020).
Furuya A, Uozaki M, Yamasaki H, Arakawa T, Arita M, Koyama AH. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. International Journal of Molecular Medicine. 2008; 22: 541–545.
Sangani R, Periyasamy-Thandavan S, Pathania R, Ahmad S, Kutiyanawalla A, Kolhe R, et al. The crucial role of vitamin C and its transporter (SVCT2) in bone marrow stromal cell autophagy and apoptosis. Stem Cell Research. 2015; 15: 312–321.
Hasanein P, Mohammadi-Raighan P, Komaki A. Vitamins C and E alone and in combination partly protect against chronic ethanol-induced toxicity in rat erythrocytes. International Journal for Vitamin and Nutrition Research. 2019; 89: 152–160.
Valiolahi M, Najafi MA, Eskandani MA, Rahnama M. Effects of organic acid alone and in combination with H2O2 and NaCl on Escherichia coli O157:H7: an evaluation of antioxidant retention and overall acceptability in Basil leaves (Ocimum basilicum). International Journal of Food Microbiology. 2019; 292: 56–63.
Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012; 2: 303–336.
Barbieri R, Coppo E, Marchese A, Daglia M, Sobarzo-Sánchez E, Nabavi SF, et al. Phytochemicals for human disease: an update on plant-derived compounds antibacterial activity. Microbiological Research. 2017; 196: 44–68.
Lage OM, Ramos MC, Calisto R, Almeida E, Vasconcelos V, Vicente F. Current screening methodologies in drug discovery for selected human diseases. Marine Drugs. 2018; 16: E279.
Paital B. Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context. Science of the Total Environment. 2020; 729: 139088.
Das K, Paital B. First week of social lockdown versus medical care against COVID-19 - with special reference to India. Current Trends in Biotechnology and Pharmacy. 2020; 14: 196–216.
Paital B, Das K, Parida SK. Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. Science of the Total Environment. 2020; 728: 138914.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Back to top